365 related articles for article (PubMed ID: 17868792)
1. Rationale for combining blockers of the renin-angiotensin system.
Azizi M; Wuerzner G
Semin Nephrol; 2007 Sep; 27(5):544-54. PubMed ID: 17868792
[TBL] [Abstract][Full Text] [Related]
2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
3. Recent changes in the landscape of combination RAS blockade.
Epstein BJ; Smith SM; Choksi R
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
[TBL] [Abstract][Full Text] [Related]
4. [Blockade of the renin-angiotensin system by a combination of ACE inhibitors and AT1 receptor antagonists].
Azizi M
Rev Prat; 2004 Jun; 54(11):1167-74. PubMed ID: 15496022
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of renin-angiotensin blockade in patients receiving dialysis.
Suzuki H
Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):397-405. PubMed ID: 19491138
[TBL] [Abstract][Full Text] [Related]
6. Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy.
Cohn JN; Goldman JM
Am J Hypertens; 2008 Mar; 21(3):248-56. PubMed ID: 18219303
[TBL] [Abstract][Full Text] [Related]
7. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Weber MA
Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
[TBL] [Abstract][Full Text] [Related]
8. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy.
Giles TD
Rev Cardiovasc Med; 2007; 8 Suppl 2():S14-21. PubMed ID: 17401312
[TBL] [Abstract][Full Text] [Related]
9. Renin inhibition--benefit beyond hypertension control.
Kher V
J Assoc Physicians India; 2009 Jul; 57():518-20, 525. PubMed ID: 20329413
[TBL] [Abstract][Full Text] [Related]
10. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.
Fernandez-Juárez G; Barrio V; de Vinuesa SG; Goicoechea M; Praga M; Luño J
J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270
[TBL] [Abstract][Full Text] [Related]
11. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
Bommer WJ
Prev Cardiol; 2008; 11(4):215-22. PubMed ID: 19476574
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP
J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
[TBL] [Abstract][Full Text] [Related]
13. The renin system: is direct renin inhibition different from blockade at the AT1 receptor or the ACE step?
Hollenberg NK
Rev Cardiovasc Med; 2007; 8 Suppl 2():S7-13. PubMed ID: 17401314
[TBL] [Abstract][Full Text] [Related]
14. Anti-diabetic effect of blockade of the renin-angiotensin system.
Ando K; Fujita T
Diabetes Obes Metab; 2006 Jul; 8(4):396-403. PubMed ID: 16776746
[TBL] [Abstract][Full Text] [Related]
15. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
16. Blocking the renin-angiotensin system: dual- versus mono-therapy.
Ravandi A; Teo KK
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
[TBL] [Abstract][Full Text] [Related]
17. Renin inhibition with aliskiren.
Wuerzner G; Azizi M
Clin Exp Pharmacol Physiol; 2008 Apr; 35(4):426-30. PubMed ID: 18307734
[TBL] [Abstract][Full Text] [Related]
18. Are there effects of renin-angiotensin system antagonists beyond blood pressure control?
Bakris G
Am J Cardiol; 2010 Jan; 105(1 Suppl):21A-9A. PubMed ID: 20102970
[TBL] [Abstract][Full Text] [Related]
19. [Renin-angiotensin system modulation: instructions for use].
Bellis A; Rozza F; Crispo S; Trimarco B
G Ital Cardiol (Rome); 2008 Feb; 9(2):79-89. PubMed ID: 18383770
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
